← All trials
NCT04573153
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 21, 2020
- Primary completion
- Jan 31, 2021
- Completion date
- Mar 31, 2021
- First posted
- Oct 5, 2020
- Last posted
- Oct 6, 2020
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ScandiBio Therapeutics ABLead sponsor
- Istanbul Medipol UniversityCollaborator
- Bakirkoy Dr. Sadi Konuk Research and Training HospitalCollaborator
- Kanuni Sultan Suleyman Training and Research HospitalCollaborator
- Bagcilar Research and Training HospitalCollaborator
- MonitorCROCollaborator
- Dr. Lutfi Kirdar Kartal Training and Research HospitalCollaborator
- Alanya Alaaddin Keykubat UniversityCollaborator
- Canakkale 18 Mart University Health Research and Application HospitalCollaborator
- University of Health Sciences, TurkeyOverall official - principal investigator
- Umraniye Education and Research HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.